Bethesda · Pre-Seed–Series A · 9 people tracked
Also known as EPIDAREX CAPITAL MANAGEMENT LLC · EPIDAREX CAPITAL US
Investment thesis
Epidarex is a transatlantic early-stage venture capital firm that invests in and helps build breakthrough life science companies located in emerging innovation hubs. Led by a diverse team of early-stage investors, the firm positions itself as a trusted partner to founders and co-investors, leveraging deep scientific and industry networks to create value and drive shared success across its portfolio.
Source: firm website, verified Aug 25, 2026.
Team · 9 people
from public directories
What they invest in
from 23 of 39 portfolio companiesBiotech ×21Healthtech ×14Medical Devices ×8Deep Tech ×3AI & Machine Learning ×2Longevity ×2Digital Health ×1Impact & Social Good ×1
HQs:United States×8United Kingdom×5Germany×1
Investments · 39 tracked
founders shown can be your intro pathBy year:2022 · 12020 · 12016 · 12015 · 14 dated
Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.
BiotechHealthtech
Jan Thirkettle(CEO Director)
Co-investorsOno Venture Investment, Inc.Dementia Discovery FundSV Health Investors
LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk.
BiotechHealthtechMedical DevicesLeeds, GB
Professor Helen Philippou(Scientific Founder)Dr. Richard Foster(Scientific Founder)
Macomics is a drug discovery company developing therapies that target macrophage activity for diseases with limited or ineffective treatment options.
BiotechLongevity
Co-investorsScottish Enterprise
Nyra Medical develops the CARLEN (Cardiac Leaflet Enhancer) system, a transcatheter single-leaflet device for repairing functional mitral regurgitation while preserving native valve function.
BiotechHealthtechMedical DevicesAtlanta, US
Dr. Murali Padala(Founder)Dr. Eric Sarin(Founder, Director)Dr. Kirthana Suresh(Founder)Sai Muralidhar Padala(Executive Officer, Director)Murali Padala(Co-founder)Eric Sarin(Co-founder)
Co-investorsBroadview VenturesVensana CapitalGRA Venture
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.
BiotechHealthtech
Co-investorsOxford Science EnterprisesSound BioventuresTaiho Ventures, LLCM Ventures
Technology-focused company on rational drug design for cancer and chronic inflammatory diseases (acquired by Aclaris Therapeutics in August 2017).
HealthtechSaint Louis, US
Jennifer Bohnert(Executive Officer)Walter Smith(Executive Officer, Director)Joseph Monahan(Executive Officer, Director)
BoardDaniel Janiak(Director)Charles Bolten(Director)Thomas Smart(Director)
Board seatKyparissia Sirinakis· per SEC Form D
University of Maryland spin-out commercializing minimally invasive image-guided surgical tool for beating heart mitral valve repair (acquired by Edwards Lifesciences in December 2017).
BiotechBaltimore, US
James Gammie(Director)Mark Collins(Executive Officer)Peter Boyd(Executive Officer)William Niland(Executive Officer, Director)
BoardJames Cox(Director)
Board seatKyparissia Sirinakis· per SEC Form D
Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases.
BiotechDigital HealthMedical DevicesCharlottesville, US
Robert Creeden(Director)Kurt Woerpel(Executive Officer)Andrew J Krouse(Executive Officer, Director)
Board seatKyparissia Sirinakis· per SEC Form D
Co-investorsVTC Ventures
Developing new modulators of the adenosine pathway for cancer treatment.
Co-investorsAvoro Capital AdvisorsF-Prime CapitalKeyhorse CapitalSofinnova VenturesSolasta VenturesvenBio Partners
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
Crestwood, US
Co-investorsEMBL VenturesvenBio Partners
University of Glasgow spin-out with pioneering CellOPTIQ technology to evaluate cardiotoxicity risk in pharmaceuticals.
Clyde Biosciences is a contract research organization offering predictive cardiac safety and efficacy testing using human iPSC-derived cardiomyocyte models, aimed at pharmaceutical and biotech teams assessing cardiotoxicity for clinical translation.
BiotechDeep TechHealthtech
Godfrey Smith(Chief Scientific Officer and Co-Founder)Francis Burton(Head of Software and Modeling & Co-Founder)Richard Henderson(Chief Executive Officer)Mark Bryant(Chief Business Officer)
Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets.
AI & Machine LearningBiotech
Co-investorsPfizer Venture InvestmentsColumbus Venture Partners
Co-investorsBioGeneration Ventures
Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD.
BiotechDeep TechCambridge, GB
Pearl Huang(President & CEO)Stephen Huhn(CMO)
Co-investorsBGVAlpha Wave Global
University of Edinburgh spin-out clinical-phase biotech developing C-Met molecular targeting technology for cancer radiotherapy and imaging.
Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.
BiotechHealthtechBrighton, GB
John Ford(Co-founder)Martin Gosling(Founder)
Co-investorsVersant Ventures
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)Cristina Oliva(Chief Medical Officer)Nick Robbins-Cherry(Chief Financial Officer)Elizabeth Hardaker(Chief Translational Science Officer)
Co-investors3B Future Health FundAlbionVCGlobal BioAccess FundNovartis Venture FundUCL Technology FundBioGeneration Ventures
RNA-targeted company focused on upregulating new targets to transform treatment of neurodegenerative diseases.
The National Kidney Foundation is a nonprofit organization focused on kidney disease, providing patient education, emotional support, and resources for patients, families, living donors, and transplant recipients.
HealthtechImpact & Social Good
Co-investorsYsios CapitalBioGeneration VenturesRoche Venture FundScottish National Investment BankSofinnova Partners
Emory University spin-out developing novel nucleic acid-based targeted delivery platform for cancer therapeutics.
Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments.
AI & Machine LearningBiotechMedical DevicesAtlanta, US
Anthony Johnson(Co-Founder & CEO)inDr. Leon Bernal-Mizrachi(Co-Founder, CSO)in
Co-investorsGRA VentureIllumina Ventures
University of Edinburgh spin-out immunemetabolic company with expertise in the kynurenine pathway and KMO biology.
Preclinical-stage drug discovery company co-founded by Epidarex-Exeed and Axxam developing first-in-class precision medicines for epileptic and neurological disorders.
Lario Therapeutics develops first-in-class precision medicines aimed at disease-modifying treatments for severe neurological disorders, including developmental and epileptic encephalopathies and Parkinson's disease.
BiotechDeep Tech
Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors.
BiotechHealthtechLondon, GB
John Maher(Founder)
Co-investorsSofinnova PartnersVulpes Investment Management
Libra Therapeutics develops small molecule therapeutics targeting lysosomal function and autophagy to treat neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's disease.
BiotechLongevityMedical Devices
Dr. Gill(Chief Scientific Officer)
Co-investorsDolby Family Ventures
Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.
BiotechMedical Devices
Adele Rowley(Chief Scientific Officer)
Co-investorsRoche Venture FundSofinnova PartnersBioGeneration VenturesScottish National Investment Bank
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)Chris Guiffre(Executive Team)Alan P. Watt(Executive Team)Jyothis George(Chief Medical Officer)Nick Clarke(Executive Team)
Co-investors5AM VenturesF-Prime CapitalSanofi VenturesSofinnova Partners
Medical technology company developing next-generation stroke aspiration technology
Co-investorsHatteras Venture Partners
RapidPulse is a medical device company developing technology for the treatment of ischemic stroke, currently conducting a pivotal clinical study.
BiotechHealthtechMedical Devices
Co-investorsBroadview VenturesHatteras Venture Partners
Ryme Medical develops a catheter-based therapy to treat chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving patient outcomes.
BiotechHealthtechMedical DevicesMountain View, US
Co-investorsSeroba Life Sciences
University of Aberdeen spin-out developing nano-synthetic bone graft substitutes using advanced nanostructures for bone repair (acquired November 2020).
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.
BiotechHealthtech
Hugo Fry(Chief Executive Officer)Christian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)
Co-investorsEMBL VenturesBoehringer Ingelheim Venture FundGimvBioMedPartners
Exits · 2
IPOs and acquisitions across the tracked portfolioConfluence Life Sciencesacq. by Aclaris TherapeuticsHarpoon Medical, Inc.acq. by Edwards Lifesciences
Portfolio news
latest coverage across their companiesMironid · eu-startups.com · Aug 7, 2026
Kidney · eu-startups.com · Aug 7, 2026
Frequently asked questions
- How many investments has Epidarex Capital made?
- Epidarex Capital has 38 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does Epidarex Capital invest at?
- Epidarex Capital invests at the Pre-Seed, Seed, Series A stages.
- What is Epidarex Capital's typical check size?
- Epidarex Capital typically writes checks of $2.5M – $6.3M.
- What sectors does Epidarex Capital focus on?
- Epidarex Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Epidarex Capital located?
- Epidarex Capital is headquartered in Bethesda, US.
- Does Epidarex Capital lead rounds?
- Yes, Epidarex Capital leads investment rounds.
- Who does Epidarex Capital co-invest with?
- Epidarex Capital most often shares deals with Broadview Ventures, EMBL Ventures, F-Prime Capital, among 31 tracked co-investors.
Media · Podcasts & interviews
featuring the teamDr Peter Finan, BIA Board Member, Partner, Epidarex Capital on SVB collapse
BioIndustry Association - BIA · Peter Finan
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.